Medix Biochemica acquires myPOLS Biotec

All founders of myPOLS Biotec will remain involved in the business following the acquisition

07-Feb-2022 - Germany

Medix Biochemica has acquired 100 percent of the shares of myPOLS Biotec GmbH. As a result of the acquisition, Medix Biochemica broadens its portfolio of molecular diagnostic raw materials for the in vitro diagnostics (“IVD”) industry, complements its scientific expertise and strengthens its local presence in Western Europe. myPOLS Biotec will form a significant part of the newly established molecular diagnostics Business Unit within Medix Biochemica Group, and its high-quality operations will continue in Konstanz, Germany. All founders of myPOLS Biotec will remain involved in the business following the acquisition.

myPOLS Biotec

myPOLS Biotec molecular diagnostics labs in Konstanz, Germany.

“This acquisition is a great step towards our vision to be the first-choice, independent raw material partner for the IVD industry, and it further accelerates Medix Biochemica’s growth in molecular diagnostics reagents business which is a key strategic expansion area for us. The broad portfolio of myPOLS Biotec, including unique and innovative molecular diagnostics reagents, complements Medix Biochemica’s existing molecular diagnostics offering. With myPOLS technology, we enable customers to shorten their assay development time and complexity, and perform molecular testing directly from crude samples. We will offer more flexibility in assay development by partnering in custom development projects. We are excited about the opportunity to offer these molecular diagnostics products to our global customer base,” says Steve Ferguson, CEO of Medix Biochemica.

“We are thrilled to join Medix Biochemica Group,” says Dr. Ramon Kranaster, CEO of myPOLS Biotec. “We are looking forward to contributing to the strong growth of Medix Biochemica and we appreciate its clear focus on quality and R&D. The high scientific competence of the myPOLS team including best-in-class DNA polymerases, supports Medix Biochemica’s long term vision and focus on IVD customers’ needs.”

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...

Something is happening in the life science industry ...

This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.